Discover
BCDA
BioCardia, Inc.
1.19
2 x 0.89
2 x 1.54
bid
ask
-
0.05
4.03%
2 @ 05:47 AM
1.17 -0.02 (1.68%)
| Ytd | -4.80% | |
| 1y | -40.50% |
1.19
day range
1.25
0.78
52 week range
2.45
| Open | 1.22 | Prev Close | 1.24 | Low | 1.19 | High | 1.25 | Mkt Cap | 17.71M |
| Vol | 251.04K | Avg Vol | 3.05M | EPS | -0.85 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 1.27 | Short Ratio | 1.41 | Inst. Own | 2.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.02 | 200-d Avg | 1.24 | 1yr Est | 25.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -1.19 | -0.61 | 0.58 | 48.74% |
| 2024-08-13 | 2024-06 | -0.1 | -0.88 | -0.78 | -780.00% |
| 2024-05-14 | 2024-03 | 0 | -1.35 | N/A | N/A |
| 2024-03-27 | 2023-12 | -1.65 | -1.35 | 0.3 | 18.18% |
| 2023-11-08 | 2023-09 | -1.8 | -1.8 | N/A | N/A |
| 2023-08-09 | 2023-06 | -2.25 | -2.55 | -0.3 | -13.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-28 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-02 | ALLEN JIM L | Director | 109.67K | Stock Award(Grant) |
| 2024-12-04 | ALTMAN PETER | Chief Executive Officer | 105.58K | Purchase |
| 2024-09-02 | BLANK ANDREW SCOTT | Director | 0.00 | Stock Award(Grant) |
| 2024-01-18 | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2023-05-17 | GILLIS EDWARD M | Officer | 40.49K | Stock Award(Grant) |
| 2024-10-10 | MCCLUNG DAVID | Chief Financial Officer | 30.01K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Susquehanna International Group, LLP | 70.60K | 141.19K | 1.54% |
| 2024-09-29 | Geode Capital Management, LLC | 14.74K | 29.47K | 0.32% |
| 2024-09-29 | Vanguard Group Inc | 12.88K | 25.77K | 0.28% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 1.28K | 2.56K | 0.03% |
| 2024-09-29 | Pingora Partners LLC | 1.04K | 2.07K | 0.02% |
| 2024-09-29 | Global Retirement Partners, LLC | 411.00 | 822.00 | 0.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 12.62K | 25.23K | 0.28% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 7.97K | 15.93K | 0.17% |
| 2024-10-30 | Fidelity Total Market Index Fund | 3.24K | 6.47K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.96K | 5.93K | 0.06% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 2.16K | 4.32K | 0.05% |
| 2024-09-29 | Blackstone Alternative Multi-Strategy Fund | 47.00 | 94.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 14 | 2024-05-30 |
| 1 : 9 | 2019-06-06 |
| 1 : 12 | 2017-11-03 |
| 1 : 12 | 2017-11-02 |
| 0.1 : 1 | 2008-03-14 |
| 6 : 1 | 2004-01-06 |